NPH Neuropharm

 

TIDMNPH 
 
RNS Number : 4716J 
Neuropharm Group PLC 
31 March 2010 
 

 
+------------------------------------+------------------------------+ 
| For immediate release              |                31 March 2010 | 
+------------------------------------+------------------------------+ 
 
                              Neuropharm Group Plc 
                        ("Neuropharm" or "the Company") 
 
                                   Offer Update 
 
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on 
neurodevelopmental disorders, provides the following update to shareholders. 
While discussions regarding a sale of one or more of the Company's pipeline 
assets are continuing, Neuropharm has received confirmation from each of the 
companies with which it has been in discussions that none of them is currently 
considering making an offer for the Company. As a result, the Company is no 
longer considered to be in an offer period for the purposes of the Takeover 
Code. 
 
As previously announced, on 10 March 2010, the Company is also making 
preparations for a Members' Voluntary Liquidation of the Company. 
 
 
For further information please contact: 
 
+----------------------------------------+----------------+ 
| Neuropharm                             | + 44 (0) 1372  | 
|                                        | 371 171        | 
+----------------------------------------+----------------+ 
| Robert Mansfield, Chief Executive      |                | 
| Officer                                |                | 
| Graham Yeatman, Chief Financial        |                | 
| Officer                                |                | 
+----------------------------------------+----------------+ 
|                                        |                | 
+----------------------------------------+----------------+ 
| Piper Jaffray Ltd.                     | + 44 (0) 20    | 
|                                        | 3142 8700      | 
+----------------------------------------+----------------+ 
| Neil Mackison, Rupert Winckler         |                | 
+----------------------------------------+----------------+ 
|                                        |                | 
+----------------------------------------+----------------+ 
| Buchanan Communications                | + 44 (0) 20    | 
|                                        | 7466 5000      | 
+----------------------------------------+----------------+ 
| Mark Court                             |                | 
+----------------------------------------+----------------+ 
 
Notes to Editors: 
 
About Neuropharm 
Neuropharm is a speciality pharmaceutical company focused on the development of 
medicines for the treatment and management of neurodevelopmental disorders. 
Please visit www.neuropharm.co.uk for further information. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCKKKDKCBKDKNN 
 

Neuropharm (LSE:NPH)
Historical Stock Chart
From Nov 2024 to Dec 2024

Neuropharm (LSE:NPH)
Historical Stock Chart
From Dec 2023 to Dec 2024